Fact CheckerSign in

NCT07324850Not yet recruitingPhase 1

A Study of SGB-7342 in Subjects With Obesity or Overweight

A Phase 1, Randomized, Double-blind, Placebo-controlled Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered SGB-7342 in Subjects With Obesity or Overweight

Source: ClinicalTrials.gov · Last updated 9 Jan 2026

Brief summary (registry, in English)

The purpose of this study is to evaluate the safety and tolerability of subcutaneously administered SGB-7342 in adult subjects with obesity and overweight.

Status (registry)
Not yet recruiting
Phase (registry)
Phase 1
Study type
Interventional
Enrollment
45 (estimated)
First submitted
23 Dec 2025
Start date
12 Jan 2026
Primary completion date
28 Oct 2026
Lead sponsor
Suzhou Sanegene Bio Inc.
Diseases
Obesity
NCT number
NCT07324850

What you commit to

  • Study type: Interventional · Phase 1
  • Planned participants: 45
  • From 12 Jan 2026 to the primary completion date, 28 Oct 2026
  • No sites listed in no country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Use of GLP-1R agonists for any indication within 6 months prior to administering the investigational drug.
  • Use of non-GLP1R medications for weight loss within 3 months prior to administering the investigational drug.

Other illness

  • A history of or a current surgical or medical condition that, in the opinion of the Investigator, may put the subject at significant risk (according to Investigator's judgment) or interfere with the subject's participation in the clinical study.

Lab values

  • Alanine aminotransferase (ALT), total bilirubin (TBIL), aspartate aminotransferase (AST)\> 1.5 × ULN, and deemed clinically significant by the Investigators

Who the study is looking for

  • Body Mass Index (BMI) within the range of 26.0 to 35.0 kg/m²
  • Have a stable body weight within 3 months
  • Participants must agree to use adequate contraception from signing the informed consent until 6 months after completion of the follow-up visit.
  • Willing to comply with the protocol required visit schedule and visit requirements and provide written informed consent.

Age in the registry: 18 years to 55 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

This page is information, not medical advice. Discuss any trial with your doctor.